Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning
暂无分享,去创建一个
J. Sierra | M. Labopin | A. Nagler | M. Mohty | D. Niederwieser | G. Ehninger | H. Veelken | A. Bacigalupo | L. Volin | A. Shimoni | D. Bunjes | B. Savani | J. Kuball | M. Eder | N. Schaap | S. Vigouroux
[1] M. Labopin,et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.
[2] P. Chiusolo,et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. , 2015, The Lancet. Oncology.
[3] E. Vellenga,et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years , 2014, Leukemia.
[4] Jianfeng Zhou,et al. Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. , 2014, International journal of clinical and experimental medicine.
[5] C. Craddock,et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia , 2014, Leukemia.
[6] F. W. Jamaluddin,et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. , 2014, Stem cells and development.
[7] M. Sorror,et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] Alan M. Miller,et al. Providing personalized prognostic information for adult leukemia survivors. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] N. Kröger,et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT , 2013, Bone Marrow Transplantation.
[10] N. Majhail,et al. Surviving the cure: long term followup of hematopoietic cell transplant recipients , 2013, Bone Marrow Transplantation.
[11] A. Nagler,et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced , 2013, Leukemia.
[12] W. Hiddemann,et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. , 2012, The Lancet. Oncology.
[13] R. Gale,et al. SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS , 2011, Bone Marrow Transplantation.
[14] A. Nagler,et al. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. , 2011, Best practice & research. Clinical haematology.
[15] M. Sorror,et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Michael Boeckh,et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.
[17] L. Robison,et al. Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. , 2010, Blood.
[18] M. Labopin,et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Nademanee,et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. , 2007, Blood.
[20] A. Nagler,et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.
[21] J. Esteve,et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.
[22] N. Ueno,et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. , 2000, British journal of haematology.
[23] J. V. Stone,et al. Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .
[24] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[25] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[26] J. V. Stone,et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. , 1999, The New England journal of medicine.
[27] K C Cain,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.